Meyahealth
HomeGeneticsGeneSGCA gene
Back to Gene
SGCA gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

SGCA gene

The SGCA gene provides instructions for creating the alpha-sarcoglycan protein, a critical component for maintaining the structural integrity of muscle cells.

Normal Function

The SGCA gene provides instructions for making the alpha component (subunit) of the sarcoglycan protein complex. This complex is located in the membrane surrounding muscle cells and helps maintain the structure of muscle tissue by stabilizing the dystrophin complex.

The dystrophin complex, which includes proteins called dystrophins and dystroglycans, acts as an anchor that connects the muscle cell's internal structural framework (cytoskeleton) to the lattice of proteins outside the cell (extracellular matrix). This connection strengthens muscle fibers and protects them from injury during the processes of muscle contraction and relaxation.

Health Conditions Related to Genetic Changes

Limb-girdle muscular dystrophy

Mutations in the SGCA gene are associated with limb-girdle muscular dystrophy.

Genomic Location

The SGCA gene is found on chromosome 17.

Frequently Asked Questions

lpha-sarcoglycan deficiency, a form of limb-girdle muscular dystrophy (LGMD), typically presents in childhood or early adulthood with progressive weakness in the hips, shoulders, and thighs. Unlike some other muscular dystrophies that may primarily affect the face or distal limbs, this condition often leads to difficulty climbing stairs, rising from a chair, or lifting arms overhead. The progression is generally slower than Duchenne muscular dystrophy but faster than some milder LGMD subtypes, and it can eventually affect the heart and respiratory muscles if not monitored.
Currently, there is no cure for SGCA-related muscular dystrophy. Treatment focuses on managing symptoms and slowing progression. This includes regular physical therapy to maintain muscle strength and flexibility, orthopedic interventions to correct joint contractures, and cardiac monitoring to detect and treat heart rhythm abnormalities. Research into gene therapy and protein replacement strategies is ongoing, but these are not yet available as standard clinical treatments.
Diagnosis typically involves a combination of clinical evaluation, blood tests, and genetic testing. A creatine kinase (CK) blood test is usually elevated, indicating muscle damage. A muscle biopsy may be performed to confirm the absence or reduction of alpha-sarcoglycan protein. Definitive diagnosis is achieved through genetic testing that identifies pathogenic variants in the SGCA gene. Electromyography (EMG) may also be used to assess the electrical activity of the muscles and distinguish this condition from other neuromuscular disorders.
Early signs often include a delayed walking milestone, frequent falls, or difficulty running and jumping compared to peers. Parents may notice a "waddling" gait or an inability to climb stairs without using their hands for support. Another common early indicator is calf pseudohypertrophy, where the calf muscles appear unusually large due to fat and connective tissue replacing muscle fibers. If a child exhibits these signs, a referral to a pediatric neurologist or geneticist is recommended.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ